Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PTGX

Protagonist Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PTGX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.03

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 16:46 UTC.

What Protagonist Therapeutics, Inc. does

Protagonist Therapeutics is a discovery and development company focused on creating medicines in inflammation and immunology, hematology, and metabolic diseases. The company has two marketed-stage programs: Icotyde, a first-in-class oral peptide for psoriasis licensed to Johnson & Johnson, and Rusfertide, an injectable hepcidin mimetic for polycythemia vera developed with Takeda Pharmaceuticals.

Summarized from Protagonist Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$1.03
Return on equity-21.17%

Revenue, margins & earnings

FY2021: net loss $126M on revenue $27M$27MFY2021FY2022: net loss $127M on revenue $27M$27MFY2022FY2023: net loss $79M on revenue $60M$60MFY2023FY2024 Revenue: $434M — margin split not shown (non-operating gains)$434MFY2024FY2025: net loss $130M on revenue $46M$46MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02Chief Financial OfficerOption exercise28,438$666.0K
  • 2026-10-02Chief Financial OfficerOption exercise9,229$359.7K
  • 2026-10-02Chief Financial OfficerOption exercise15,650$300.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics is a discovery and development company focused on creating medicines in inflammation and immunology, hematology, and metabolic diseases.

When did PTGX last file with the SEC?

Protagonist Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 16:46 UTC. This page is also available as JSON at /api/data?ticker=PTGX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PTGX and 5,000+ tickers.

Create a free account — keep PTGX
For your agent
GET /api/data?ticker=PTGX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt